Company / Cash & Equivalents
Terns Pharmaceuticals, Inc. Cash & Equivalents History
FY2020-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$161.4M
FY2024
5-year range
$47.7M / $161.4M
FY2020-FY2024
Trend
+102.0%
vs FY2023
Sector context
#110 of 208
Health Care
What the data says
At $161M, Terns Pharmaceuticals, Inc.'s cash & equivalents ranks #110 of 208 in the Health Care sector. Cash & Equivalents has fluctuated over the past 5 years, ranging from $48M in FY2021 to $161M in FY2024.
Based on SEC 10-K filings.
$161M in FY2024 with a 3-year CAGR of +50.1%.
Improved from $143M to $161M over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- +50.1%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#110 of 208 in Health CareTop 53% of 208This company $161.4M Sector average $694.3M
▼
-76.7% below sector average
Key checks
Key Insights
- 3-year CAGR of +50.1%, indicating consistent growth.
- In FY2024, cash & equivalents increased 102.0% year-over-year.
- Ranks #110 out of 208 companies in the Health Care sector.
- Lowest cash & equivalents in the period was in FY2021.
Company context
Key Data Points
- Altman Z-Score 7.86 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $161.4M | +102.0% |
| FY2023 | $79.9M | -44.2% |
| FY2022 | $143.2M | +200.3% |
| FY2021 | $47.7M | -36.3% |
| FY2020 | $74.9M | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026